In this issue: dengue fever vaccine controversy, the problem of manipulated data, fixing...
- Pharma Technology Focus: the dengue dilemma
- Personalised cell therapy developer Achilles closes £100m round
- The Ferrari of medical machinery: How one solution impressed Arimpek
- Novartis defends Zolgensma in face of FDA’s data concerns
- Targeting MND-causing genetic mutations to support drug development
Partnerships with CDMOs will be a key growth driver for gene therapy
Companies that develop gene-based therapies often need to think in advance about how they want to develop a product, including the decision of whether to invest in a manufacturing facility or CDMO.
Tripharm’s Pharmaceutical Manufacturing Centre, North Carolina
TriPharm Services, a contract development and manufacturing organisation (CDMO), is developing a pharmaceutical manufacturing centre in Morrisville, North Carolina, US.
‘Gene-ie in a bottle’ gene therapy opportunity is a treasure trove but CMOs lack capacity
CMOs are recognising the coming demand for gene therapies and have started to build production capacity, but compared with other biologic therapies there are far fewer gene therapy contract manufacturing sites worldwide.
Managing Analytical Methods Across all Stages of their Lifecycle
Chromatographic modelling using DryLab®4 software from Molnár Institute saves time and resources across all three stages of the lifecycle of an analytical method.
Sanofi’s Digital Manufacturing Facility, Massachusetts
Sanofi, a biopharmaceutical company based in France, opened a digital biopharmaceutical manufacturing facility in Framingham, Massachusetts, US, in October 2019.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.